Cargando…

TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells

Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved progression-free survival in hormone-receptor-positive (HR+), human-epidermal-growth-factor-receptor-type-2-negative (HER2−) metastatic luminal breast cancer (mLBC). Several studies have shown that in patients with endocrine-se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cordani, Nicoletta, Mologni, Luca, Piazza, Rocco, Tettamanti, Pietro, Cogliati, Viola, Mauri, Mario, Villa, Matteo, Malighetti, Federica, Di Bella, Camillo, Jaconi, Marta, Cerrito, Maria Grazia, Cavaletti, Guido, Lavitrano, Marialuisa, Cazzaniga, Marina Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671583/ https://www.ncbi.nlm.nih.gov/pubmed/38003483 http://dx.doi.org/10.3390/ijms242216294

Ejemplares similares

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
por: Cogliati, Viola, et al.
Publicado: (2022)

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
por: Cazzaniga, Marina Elena, et al.
Publicado: (2022)

Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC)
por: Cordani, Nicoletta, et al.
Publicado: (2023)

Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation
por: Scagliotti, Arianna, et al.
Publicado: (2022)

BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022)

P1235: INVESTIGATION OF THE CO-MUTATIONAL LANDSCAPE OF ALK-POSITIVE ALCL
por: Villa, Matteo, et al.
Publicado: (2023)

p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors
por: Grassilli, Emanuela, et al.
Publicado: (2021)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia
por: Aroldi, Andrea, et al.
Publicado: (2023)

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
por: Pepe, F. F., et al.
Publicado: (2022)

Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling
por: Ceccon, Monica, et al.
Publicado: (2018)

GSK3A Is Redundant with GSK3B in Modulating Drug Resistance and Chemotherapy-Induced Necroptosis
por: Grassilli, Emanuela, et al.
Publicado: (2014)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
por: Li, Zhen, et al.
Publicado: (2020)

Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients
por: Fontana, Diletta, et al.
Publicado: (2023)

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study
por: Cerrito, Maria Grazia, et al.
Publicado: (2018)

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
por: Malighetti, Federica, et al.
Publicado: (2023)

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything
por: Capici, Serena, et al.
Publicado: (2022)

Insights into the Peritumoural Brain Zone of Glioblastoma: CDK4 and EXT2 May Be Potential Drivers of Malignancy
por: Giambra, Martina, et al.
Publicado: (2023)

Phosphorylation of USP29 by CDK1 Governs TWIST1 Stability and Oncogenic Functions
por: Guan, Tangming, et al.
Publicado: (2023)

Human Chromosome 18 and Acrocentrics: A Dangerous Liaison
por: Villa, Nicoletta, et al.
Publicado: (2021)

Long Non-Coding RNAs and Related Molecular Pathways in the Pathogenesis of Epilepsy
por: Villa, Chiara, et al.
Publicado: (2019)

An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization
por: Crespiatico, Ilaria, et al.
Publicado: (2019)

Unexpected frequency of genomic alterations in histologically normal colonic tissue from colon cancer patients
por: Conconi, Donatella, et al.
Publicado: (2016)

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015)

Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights
por: Villa, Chiara, et al.
Publicado: (2020)

Patient-Derived Induced Pluripotent Stem Cells (iPSCs) and Cerebral Organoids for Drug Screening and Development in Autism Spectrum Disorder: Opportunities and Challenges
por: Villa, Chiara, et al.
Publicado: (2021)

Can SARS-CoV-2 Infection Exacerbate Alzheimer’s Disease? An Overview of Shared Risk Factors and Pathogenetic Mechanisms
por: Villa, Chiara, et al.
Publicado: (2022)

OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes
por: Rocco, Piazza, et al.
Publicado: (2017)

Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes
por: Piazza, Rocco, et al.
Publicado: (2017)

Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
por: Liu, Jingyi, et al.
Publicado: (2018)

Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer
por: Gomes, Inês, et al.
Publicado: (2023)

High phosphorylated cyclin-dependent kinase 2 expression indicates poor prognosis of luminal androgen receptor triple-negative breast cancer: pCDK2 in luminal androgen receptor TNBC
por: Jin, Zining, et al.
Publicado: (2022)

THE TOTAL LUMINOUS EFFICIENCY OF LUMINOUS BACTERIA
por: Harvey, E. Newton
Publicado: (1925)

Simultaneous Overexpression of Functional Human HO-1, E5NT and ENTPD1 Protects Murine Fibroblasts against TNF-α-Induced Injury In Vitro
por: Cinti, Alessandro, et al.
Publicado: (2015)

A Systematic Review of the Current Status and Quality of Radiomics for Glioma Differential Diagnosis
por: Brancato, Valentina, et al.
Publicado: (2022)

An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective
por: Cordani, Nicoletta, et al.
Publicado: (2023)

19q12q13.2 duplication syndrome: neuropsychiatric long-term follow-up of a new case and literature update
por: Nacinovich, Renata, et al.
Publicado: (2017)

Are circadian amplitudes and periods correlated? A new twist in the story
por: del Olmo, Marta, et al.
Publicado: (2023)

Twisted Radio Waves and Twisted Thermodynamics
por: Kish, Laszlo B., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t6adpdcop9avc0nvfoa2piug1o